AI Stock Analysis - Cybin (CYBN)
Analysis generated August 21, 2025.
Cybin is a biopharmaceutical company focused on progressing psychedelic therapeutics through clinical trials and into the market. With a commitment to addressing the mental health crisis, Cybin’s innovative approach leverages the therapeutic potential of psychedelic compounds, often in conjunction with psychotherapy, to treat complex mental health issues. The company is at the forefront of this emerging field and aims to transform the landscape of mental health care.
Stock Alerts - Cybin (CYBN)
 |
Cybin | December 31 Price is down by -6.8% in the last 24h. |
|
Cybin | December 23 Price is up by 7.6% in the last 24h. |
|
Cybin | December 19 Price is up by 6.2% in the last 24h. |
|
Cybin | December 12 Price is up by 7.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Cybin
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 30,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 19 | Sign up | Sign up | Sign up |
| Facebook Followers | 11,642 | Sign up | Sign up | Sign up |
| Instagram Followers | 15,108 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 63 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,552 | Sign up | Sign up | Sign up |
| X Followers | 9,320 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 49 | Sign up | Sign up | Sign up |
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
| Price | $8.28 |
| Target Price | Sign up |
| Volume | 713,590 |
| Market Cap | $413M |
| Year Range | $5.51 - $9 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cybin to change name, symbolJanuary 5 - Thefly.com |
 |
Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For MomentumJanuary 1 - SeekingAlpha |
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business HighlightsFebruary 13 - Financial Post |
|
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ExecutionFebruary 10 - Financial Post |
|
How magnetic fields, psychedelics and ketamine are helping treat the brainFebruary 5 - ABC News (AU) |
|
 |
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on NasdaqJanuary 6 - Antaranews.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -34M | -29M | -1.390 |
| Q2 '25 | 0 | 0 | 0 | -25M | -25M | -1.460 |
| Q1 '25 | 0 | 0 | 0 | -31M | 0 | -1.460 |
| Q4 '24 | 0 | 0 | 0 | -11M | -31M | -0.530 |
| Q3 '24 | 0 | 0 | 0 | -57M | -58M | -2.860 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Cybin (CYBN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Cybin
The Market Cap of Cybin is $413M.
Currently, the price of one share of Cybin stock is $8.28.
The CYBN stock price chart above provides a comprehensive visual representation of Cybin's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cybin shares. Our platform offers an up-to-date CYBN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Cybin (CYBN) does not offer dividends to its shareholders. Investors interested in Cybin should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Cybin are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
